Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

NCT03284853 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

436

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: Netarsudil/Latanoprost 0.02%/0.005%
DRUG: GANFORT®

Sponsor

Aerie Pharmaceuticals